While previous clinical trials suggest that adjuvant therapy with cisplatin-based regimens does not improve survival in patients with early-stage TP53-mutant NSCLC relative to patients with TP53-wild type disease14,15, other therapies (e.g., immunotherapy) could provide a survival advantage to this population16. The gene discussed is TP53; the disease is non-small cell lung carcinoma.